Browse Technologies

Displaying 11 - 20 of 182


Portfolio of Continuum Robotic Systems, Algorithms, and Software Technologies from the Robotics Lab of Professor Nabil Simaan

Professor Simaan and his lab have years of experiencing working collaboratively with commercial entities of various sizes. His research is focused on advanced robotics, mechanism design, control, and telemanipulation for medical applications. His projects have led the way in advancing several robotics technologies for medical applications including high dexterity, snake-like robots for surgery, steerable electrode arrays for cochlear implant surgery, robotics for single port access surgery, and natural orifice surgery.


Licensing Contact

Masood Machingal

615.343.3548
Medical Devices
Genitourinary

Small Molecule mGlu3 NAMs as Therapeutics for CNS Disorders

The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has a mission to promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at over 10 different pharmaceutical companies to ensure a diverse set of approaches, techniques and philosophies to advancing compounds. Together they aim to de-risk drug discovery programs.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Small Molecule

mGlu3 NAMs as Therapeutics for Chemoresistant Tumors

Targeting metabotropic glutamate receptor 3 (mGlu3) has been linked as a potential therapeutic to many neurological disorders and well as oncology through the use of dual specific mGlu2/3 Antagonists (LY341495, RO4491533, MGS0039, RO4988546).


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Small Molecule

Novel anti-platelet therapy for treatment of thrombosis, cardiovascular disease, and cerebrovascular injury

One of the leading causes of deaths in developed countries is related to thromboembolism. PAR-4 (protease activated receptor-4) is one of two receptors on the human platelet that respond to thrombin, the central enzyme of coagulation.  Researchers here at Vanderbilt University have developed novel antagonists of PAR-4 that could be beneficial for patients allowing for normal hemostasis during treatment for thrombotic events.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Cardiovascular

Organ-on-a-Chip System

Vanderbilt researchers have developed a group of microfluidic organ-on-chip devices that include perfusion controllers, microclinical analyzers, microformulators, and integrated microfluidic measurement chips. Together, these devices can measure and control multiple organ-on-chip systems in order to model the multi-organ physiology of humans.


Licensing Contact

Ashok Choudhury

615.322.2503
Microfluidics

IntelliCane: Instrumented cane for diagnosis and evaluation of gait behavior in individuals with mobility issues.

This device is designed to assist physical therapists in collection of objective data during gait analysis, to facilitate appropriate assistive gait device prescription, to provide patients and therapists feedback during gait training, and to reduce wrist and shoulder injuries with cane usage.Currently gait characteristics are "measured" in a clinic-based atmosphere. This has two limitations: (i) subjective allocation of "measures" of gait characteristics and (ii) limited data based on trials in the clinic ONLY. What this technology is designed to do is achieve freedom from both of these limitations. The measurements are objective and numerical values (force etc.) and the clinic could provide the cane to the user for obtaining a much more extensive data set including use during normal life activities at home etc.


Licensing Contact

Masood Machingal

615.343.3548
Medical Devices

The Adventures of Jasper Woodbury: Videodisc-Based Adventures That Focus on Mathematical Problem Finding and Problem Solving Designed for Students in Grades 5 and Up

The Adventures of Jasper Woodbury™ consists of 12 videodisc-based adventures that focus on mathematical problem finding and problem solving. In particular, each adventure provides multiple opportunities for problem solving, reasoning, communication and making connections to other areas such as science, social studies, literature and history. Jasper adventures are designed for students in grades 5 and up. Each videodisc contains a short (approximately 17 minute) video adventure that ends in a complex challenge. The adventures are designed like good detective novels where all the data necessary to solve the adventure (plus additional data that are not relevant to the solution) are embedded in the story. Jasper adventures also contain ""embedded teaching"" episodes that provide models of particular approaches to solving problems.


Licensing Contact

Masood Machingal

615.343.3548
Education

Long-Lasting and Self-Sustaining Cell Therapy System

Researchers at Vanderbilt have created a novel drug delivery system using two distinct T-cell populations that interact to promote engraftment and persistence in pre-clinical models, increasing the efficacy of T-cell therapies. Furthermore, "booster" treatments can be administered months after the first dose to produce an expansion of antigen specific T cells. These advantages result in longer-term therapeutic efficacy and could reduce the number of treatments required. This system also represents a viable self-renewing platform for the delivery of biologic drugs in patients who would otherwise require frequent administration.


Licensing Contact

Cameron Sargent

615.322.5907

New antibiotics against new targets in multi-drug resistant microorganisms

New everninomicin antibiotics including a potent bifunctional antibiotic natural product targeting two different and distant ribosomal sites are under development and can be readily produced using synthetic biology. Developing resistance to this bidentate antibiotic should be very difficult for pathogenic microorganisms.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Infectious Disease

New Drug for Blood Clot: FXII Inhibitors to Treat Thrombosis

Thrombosis is the formation of a blood clot inside a blood vessel, which may cause reduced blood flow to a tissue, or even tissue death. Thrombosis, inflammation, and infections are responsible for >70% of all human mortality. Thrombosis is also the major factor for heart disease and stroke. 500,000 die from thrombosis every year in Europe. Inhibitory treatment of these conditions may also improve the outcomes of several non-fatal diseases. Researchers from Vanderbilt University and Oregon Health & Science University have jointly discovered new monoclonal antibodies that potently inhibit the blood coagulation protein factor XII (FXII), a critical player in the pathway, and anticoagulate blood. This invention provides foundation for commercial development of anti-thrombotic drugs based on new molecular entities.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Antibody
Assays/Screening